GLASF
Price
$7.55
Change
+$0.29 (+3.99%)
Updated
Sep 5 closing price
Capitalization
583.26M
HYPMY
Price
$4.21
Change
+$0.07 (+1.69%)
Updated
Sep 5 closing price
Capitalization
2.7B
Interact to see
Advertisement

GLASF vs HYPMY

Header iconGLASF vs HYPMY Comparison
Open Charts GLASF vs HYPMYBanner chart's image
Glass House Brands
Price$7.55
Change+$0.29 (+3.99%)
Volume$119.09K
Capitalization583.26M
Hypera SA
Price$4.21
Change+$0.07 (+1.69%)
Volume$1.55K
Capitalization2.7B
GLASF vs HYPMY Comparison Chart in %
Loading...
GLASF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HYPMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GLASF vs. HYPMY commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GLASF is a Hold and HYPMY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (GLASF: $7.55 vs. HYPMY: $4.22)
Brand notoriety: GLASF and HYPMY are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: GLASF: 37% vs. HYPMY: 1%
Market capitalization -- GLASF: $583.26M vs. HYPMY: $2.7B
GLASF [@Pharmaceuticals: Generic] is valued at $583.26M. HYPMY’s [@Pharmaceuticals: Generic] market capitalization is $2.7B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.94B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GLASF’s FA Score shows that 0 FA rating(s) are green whileHYPMY’s FA Score has 2 green FA rating(s).

  • GLASF’s FA Score: 0 green, 5 red.
  • HYPMY’s FA Score: 2 green, 3 red.
According to our system of comparison, HYPMY is a better buy in the long-term than GLASF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GLASF’s TA Score shows that 4 TA indicator(s) are bullish while HYPMY’s TA Score has 4 bullish TA indicator(s).

  • GLASF’s TA Score: 4 bullish, 6 bearish.
  • HYPMY’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, HYPMY is a better buy in the short-term than GLASF.

Price Growth

GLASF (@Pharmaceuticals: Generic) experienced а -8.48% price change this week, while HYPMY (@Pharmaceuticals: Generic) price change was -0.59% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.10%. For the same industry, the average monthly price growth was +12.13%, and the average quarterly price growth was +87.01%.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.10% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HYPMY($2.7B) has a higher market cap than GLASF($583M). GLASF has higher P/E ratio than HYPMY: GLASF (513.07) vs HYPMY (19.64). HYPMY YTD gains are higher at: 43.484 vs. GLASF (30.172). HYPMY has higher annual earnings (EBITDA): 1.41B vs. GLASF (49M). HYPMY has more cash in the bank: 1.2B vs. GLASF (40.7M). GLASF has less debt than HYPMY: GLASF (72.8M) vs HYPMY (8.86B). HYPMY has higher revenues than GLASF: HYPMY (6.66B) vs GLASF (222M).
GLASFHYPMYGLASF / HYPMY
Capitalization583M2.7B22%
EBITDA49M1.41B3%
Gain YTD30.17243.48469%
P/E Ratio513.0719.642,612%
Revenue222M6.66B3%
Total Cash40.7M1.2B3%
Total Debt72.8M8.86B1%
FUNDAMENTALS RATINGS
GLASF vs HYPMY: Fundamental Ratings
GLASF
HYPMY
OUTLOOK RATING
1..100
223
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
9
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9481
PRICE GROWTH RATING
1..100
4261
P/E GROWTH RATING
1..100
10011
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HYPMY's Valuation (9) in the null industry is significantly better than the same rating for GLASF (94). This means that HYPMY’s stock grew significantly faster than GLASF’s over the last 12 months.

HYPMY's Profit vs Risk Rating (100) in the null industry is in the same range as GLASF (100). This means that HYPMY’s stock grew similarly to GLASF’s over the last 12 months.

HYPMY's SMR Rating (81) in the null industry is in the same range as GLASF (94). This means that HYPMY’s stock grew similarly to GLASF’s over the last 12 months.

GLASF's Price Growth Rating (42) in the null industry is in the same range as HYPMY (61). This means that GLASF’s stock grew similarly to HYPMY’s over the last 12 months.

HYPMY's P/E Growth Rating (11) in the null industry is significantly better than the same rating for GLASF (100). This means that HYPMY’s stock grew significantly faster than GLASF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GLASFHYPMY
RSI
ODDS (%)
Bearish Trend 1 day ago
74%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
72%
Bullish Trend 1 day ago
72%
Momentum
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 1 day ago
69%
MACD
ODDS (%)
Bearish Trend 1 day ago
72%
Bullish Trend 1 day ago
72%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
72%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
66%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 25 days ago
70%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
73%
Aroon
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
GLASF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HYPMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CFJAX35.23N/A
N/A
Calvert US Large Cap Value Rspnb Idx A
PNRAX58.29N/A
N/A
Putnam Research A
RYDAX108.01N/A
N/A
Rydex Dow Jones Industrial Average® A
TRDIX8.47N/A
N/A
Transamerica Sustainable Equity Inc I2
LMGPX76.04N/A
N/A
ClearBridge International Growth IS

GLASF and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLASF has been loosely correlated with TSNDF. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if GLASF jumps, then TSNDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLASF
1D Price
Change %
GLASF100%
+3.99%
TSNDF - GLASF
63%
Loosely correlated
+13.08%
GTBIF - GLASF
62%
Loosely correlated
+4.55%
TCNNF - GLASF
60%
Loosely correlated
+4.55%
VRNOF - GLASF
58%
Loosely correlated
+5.51%
CURLF - GLASF
57%
Loosely correlated
+1.79%
More

HYPMY and

Correlation & Price change

A.I.dvisor tells us that HYPMY and PLNH have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HYPMY and PLNH's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HYPMY
1D Price
Change %
HYPMY100%
+1.57%
PLNH - HYPMY
21%
Poorly correlated
+10.91%
CPIX - HYPMY
20%
Poorly correlated
-9.56%
GLASF - HYPMY
20%
Poorly correlated
+3.99%
KMDA - HYPMY
20%
Poorly correlated
+1.13%
JUSHF - HYPMY
18%
Poorly correlated
+6.59%
More